The future of kinase inhibitors for DLBCL?

Por Herman, Sarah E. M.
Publicado no Blood (2018)

Pre-clinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the trade

Por Herman, Sarah E. M., Wiestner, Adrian
Publicado no Semin Oncol (2016)

Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL – Reply

Por Herman, Sarah E. M., Wiestner, Adrian
Publicado no Clin Cancer Res (2016)

Molecular Pathways: Targeting the Phosphoinositide 3-Kinase (PI3-Kinase) p110 delta in Chronic Lymphocytic Leukemia

Por Herman, Sarah E. M., Johnson, Amy J.
Publicado em 2012

Treatment with ibrutinib inhibits BTK and VLA-4 dependent adhesion of chronic lymphocytic leukemia cells in vivo

Por Herman, Sarah E. M., Mustafa, Rashida Z., Jones, Jade, Wong, Deanna H., Farooqui, Mohammed, Wiestner, Adrian
Publicado no Clin Cancer Res (2015)

Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL

Por Herman, Sarah E. M., Mustafa, Rashida Z., Gyamfi, Jennifer A., Pittaluga, Stefania, Chang, Stella, Chang, Betty, Farooqui, Mohammed, Wiestner, Adrian
Publicado em 2014

Polyreactive Antibodies in CLL Correlate with the Level of Immunoglobulins Not the Number of B Lymphocytes

Por Gunti, Sreenivasulu, Herman, Sarah E.M., Gottumukkala, Raju VSRK, Xoing, Ying, Sun, Clare, Carmona, Gilberto, Wiestner, Adrian, Notkins, Abner L.
Publicado no Leuk Lymphoma (2018)

TLR signaling is activated in lymph-node resident CLL cells and is only partially inhibited by ibrutinib

Por Dadashian, Eman L., McAuley, Erin M., Liu, Delong, Shaffer, Arthur L., Young, Ryan M., Iyer, Jessica R., Kruhlak, Michael J., Staudt, Louis M., Wiestner, Adrian, Herman, Sarah E. M.
Publicado no Cancer Res (2018)

The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia

Por Herman, Sarah E. M., Lapalombella, Rosa, Gordon, Amber L., Ramanunni, Asha, Blum, Kristie A., Jones, Jeffrey, Zhang, Xiaoli, Lannutti, Brian J., Puri, Kamal D., Muthusamy, Natarajan, Byrd, John C., Johnson, Amy J.
Publicado em 2011

Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicity

Por Kohrt, Holbrook E., Sagiv-Barfi, Idit, Rafiq, Sarwish, Herman, Sarah E. M., Butchar, Jonathon P., Cheney, Carolyn, Zhang, Xiaoli, Buggy, Joseph J., Muthusamy, Natarajan, Levy, Ronald, Johnson, Amy J., Byrd, John C.
Publicado em 2014

Combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 improves survival and tumor control in CLL mouse model

Por Niemann, Carsten U., Mora-Jensen, Helena I., Dadashian, Eman L., Krantz, Fanny, Covey, Todd, Chen, Shih-Shih, Chiorazzi, Nicholas, Izumi, Raquel, Ulrich, Roger, Lannutti, Brian J., Wiestner, Adrian, Herman, Sarah E. M.
Publicado no Clin Cancer Res (2017)

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

Por Herman, Sarah E. M., Gordon, Amber L., Hertlein, Erin, Ramanunni, Asha, Zhang, Xiaoli, Jaglowski, Samantha, Flynn, Joseph, Jones, Jeffrey, Blum, Kristie A., Buggy, Joseph J., Hamdy, Ahmed, Johnson, Amy J., Byrd, John C.
Publicado em 2011

A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era

Por Robinson, Hannah R., Qi, Junpeng, Cook, Erika M., Nichols, Cydney, Dadashian, Eman L., Underbayev, Chingiz, Herman, Sarah E. M., Saba, Nakhle S., Keyvanfar, Keyvan, Sun, Clare, Ahn, Inhye E., Baskar, Sivasubramanian, Rader, Christoph, Wiestner, Adrian
Publicado no Blood (2018)

Pharmacokinetics and Tissue Disposition of Lenalidomide in Mice

Por Rozewski, Darlene M., Herman, Sarah E. M., Towns, William H., Mahoney, Emilia, Stefanovski, Matthew R., Shin, Jungook D., Yang, Xiaoxia, Gao, Yue, Li, Xiaobai, Jarjoura, David, Byrd, John C., Johnson, Amy J., Phelps, Mitch A.
Publicado em 2012

MALT1 inhibition is efficacious in both naïve and ibrutinib-resistant chronic lymphocytic leukemia

Por Saba, Nakhle S., Wong, Deanna H., Tanios, Georges, Iyer, Jessica R., Lobelle-Rich, Patricia, Dadashian, Eman L., Liu, Delong, Fontan, Lorena, Flemington, Erik K., Nichols, Cydney M., Underbayev, Chingiz, Safah, Hana, Melnick, Ari, Wiestner, Adrian, Herman, Sarah E. M.
Publicado no Cancer Res (2017)

Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia

Por Yu, Bo, Mao, Yicheng, Bai, Li-Yuan, Herman, Sarah E. M., Wang, Xinmei, Ramanunni, Asha, Jin, Yan, Mo, Xiaokui, Cheney, Carolyn, Chan, Kenneth K., Jarjoura, David, Marcucci, Guido, Lee, Robert J., Byrd, John C., Lee, L. James, Muthusamy, Natarajan
Publicado em 2013

Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Por Chang, Betty Y., Francesco, Michelle, De Rooij, Martin F. M., Magadala, Padmaja, Steggerda, Susanne M., Huang, Min Mei, Kuil, Annemieke, Herman, Sarah E. M., Chang, Stella, Pals, Steven T., Wilson, Wyndham, Wiestner, Adrian, Spaargaren, Marcel, Buggy, Joseph J., Elias, Laurence
Publicado em 2013

Modeling Tumor-Host Interactions of Chronic Lymphocytic Leukemia in Xenografted Mice to Study Tumor Biology and Evaluate Targeted Therapy

Por Herman, Sarah E. M., Sun, Xiameng, McAuley, Erin M., Hsieh, Matthew M., Pittaluga, Stefania, Raffeld, Mark, Liu, Delong, Keyvanfar, Keyvan, Chapman, Colby M., Chen, Jichun, Buggy, Joseph J., Aue, Georg, Tisdale, John F., Pérez-Galán, Patricia, Wiestner, Adrian
Publicado em 2013

Interactions between ibrutinib and anti-CD20 antibodies; competing effects on the outcome of combination therapy

Por Skarzynski, Martin, Niemann, Carsten U, Lee, Yuh Shan, Martyr, Sabrina, Maric, Irina, Salem, Dalia, Stetler-Stevenson, Maryalice, Marti, Gerald E, Calvo, Katherine R, Yuan, Constance, Valdez, Janet, Soto, Susan, Farooqui, Mohammed Z.H., Herman, Sarah E.M., Wiestner, Adrian
Publicado no Clin Cancer Res (2015)

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival sig...

Por Herman, Sarah E. M., Gordon, Amber L., Wagner, Amy J., Heerema, Nyla A., Zhao, Weiqiang, Flynn, Joseph M., Jones, Jeffrey, Andritsos, Leslie, Puri, Kamal D., Lannutti, Brian J., Giese, Neill A., Zhang, Xiaoli, Wei, Lai, Byrd, John C., Johnson, Amy J.
Publicado em 2010